Based on the positive results of these trials, treatment of EGFR-mutated NSCLCs with a first- or second-generation EGFR TKI has become the standard of care for upfront therapy of advanced/metastatic disease in this small molecularly selected subgroup of patients, delaying the use of chemotherapy in subsequent treatment lines. Here, EGFR is linked to metastatic neoplasm.